RIO DE JANEIRO, BRAZIL (UroToday.com) - Presented by M.S. Rahnama’i,1 T.A. Marcelissen,2 F.H.G. Ong,3 J.T.W. Snijkers,1 P. Devries,2 G.A. van Koeveringe1 at the International Continence Society (ICS) 2014 Annual Meeting - October 20 - 24, 2014 - Rio de Janeiro, Brazil
The emerging data of intravesical botulinum toxin-A (BTA) use for treatment of idiopathic overactive bladder is showing to be an efficacious and well-tolerated alternative to the mainstay of therapy. After every injection with BTA, there is a risk of Unacceptable high post voiding residual volume and therefore, the indication to clean intermittent self- catheterisation (CISC). It is not clear if the effect of repeat BTA is different to the each prior BTA treatment. Moreover, it is not known whether the chanc of CISC increases with increasing number of BTA treatment sessions. In this study we aimed to assess the length of the effect of repeat BTA injections in the bladder of patients with an overactive bladder, due to neurogenic DO as well as idiopathic DO. Moreover, chance of CISC after each BTA treatment was evaluated...
1Maastricht Univesity Medical Centet (MUMC+), Maastricht, 2Atrium Medical Center, Heerlen, 3Orbis Medical Center, Sittard, all in The Netherlands